{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-025650","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.939650+00:00","generated_at":"2026-05-31T10:24:47.098453+00:00","sec_items":["2.02","3.03","5.03","5.07","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Monopar reports Q2 net loss $1.7M, initiates 1-for-5 reverse split to regain Nasdaq compliance","bullets":["Net loss for Q2 2024 was $1.7M ($0.10/sh) vs $2.2M ($0.16/sh) in Q2 2023; cash $7.1M sufficient through Aug 31, 2025.","MNPR-101-Zr Phase 1 imaging trial initiated and enrolling; MNPR-101-RIT therapeutic trial on track to start Q4 2024.","1-for-5 reverse stock split effective Aug 12, 2024; shares reduce from ~17.6M to ~3.5M to regain Nasdaq compliance.","Company winding down camsirubicin and MNPR-202 programs to focus on radiopharmaceutical platform.","Needs additional funding within 12 months to further advance radiopharma programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-025650","json":"https://secwatch.observer/filing/0001437749-24-025650.json","markdown":"https://secwatch.observer/filing/0001437749-24-025650.md","text":"https://secwatch.observer/filing/0001437749-24-025650.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924025650/0001437749-24-025650-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924025650/mnpr20240807_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:24:47.098453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}